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Mutations in the facilitative glucose transporter GLUT10
alter angiogenesis and cause arterial tortuosity syndrome
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Joyce E Fox4, Grazia M S Mancini2, Marios Kambouris5, Rita Gardella3, Fabio Facchetti6, Patrick J Willems7,
Ramses Forsyth8, Harry C Dietz9, Sergio Barlati3, Marina Colombi3, Bart Loeys1 & Anne De Paepe1
Arterial tortuosity syndrome (ATS) is an autosomal recessive
disorder characterized by tortuosity, elongation, stenosis and
aneurysm formation in the major arteries owing to disruption
of elastic fibers in the medial layer of the arterial wall1.
Previously, we used homozygosity mapping to map a candidate
locus in a 4.1-Mb region on chromosome 20q13.1 (ref. 2).
Here, we narrowed the candidate region to 1.2 Mb containing
seven genes. Mutations in one of these genes, SLC2A10,
encoding the facilitative glucose transporter GLUT10, were
identified in six ATS families. GLUT10 deficiency is associated
with upregulation of the TGFb pathway in the arterial wall, a
finding also observed in Loeys-Dietz syndrome, in which aortic
aneurysms associate with arterial tortuosity3. The identification
of a glucose transporter gene responsible for altered arterial
morphogenesis is notable in light of the previously suggested
link between GLUT10 and type 2 diabetes4,5. Our data
could provide new insight on the mechanisms causing
microangiopathic changes associated with diabetes and
suggest that therapeutic compounds intervening with
TGFb signaling represent a new treatment strategy.
Facilitative glucose transporters (GLUTs), encoded by a family of
SCL2A genes, are responsible for the uptake of several monosacchar-
ides, including glucose, fructose, mannose, galactose and glucosamine.
So far, mutations in two of these genes have been linked to genetic
disorders with intuitive relevance to altered glucose metabolism.
Heterozygous mutations in SLC2A1 cause a defect of glucose transport
into the brain, resulting in an epileptic encephalopathy with low
spinal-fluid glucose levels6. Homozygous mutations in SLC2A2 have
been shown to cause Fanconi-Bickel syndrome, characterized by
hepatorenal glycogen accumulation, nephropathy and diarrhea7,
whereas heterozygous mutations in this gene result in non–insulin
dependent diabetes mellitus8,9.
We report that loss-of-function mutations in a third member of the
SLC2A family, SLC2A10, cause arterial tortuosity syndrome (ATS;
OMIM 208050), an autosomal recessive condition1 characterized by
tortuosity of the large and medium-sized arteries (Fig. 1a), often
resulting in death at young age. Other typical features include
aneurysms of large arteries and stenosis of the pulmonary artery, in
association with facial features (Fig. 1b) and several connective tissue
manifestations. Histopathological findings include fragmentation of
the elastic fibers in the tunica media of the large arteries (Fig. 1c)10–13.
Previously, homozygosity mapping in 21 members of two consangui-
neous families with ATS originating from Morocco (family 1) and
Italy (family 4; Fig. 1d) assigned the gene to chromosome 20q13.1
(ref. 2). Subsequently, this localization was confirmed in four smaller
families originating from Morocco (families 2 and 3) and the Middle
East (family 5 and 6). Key recombinants delineated a candidate linkage
interval of 4.1 Mb between markers D20S836 and D20S109. We
performed further fine mapping in three families (families 1–3)
originating from the same region in Morocco, under the assumption
that one recessive ancestral mutation might have caused ATS in these
families. Families 1 and 2, but not family 3, shared haplotypes between
markers D20S888 and mSAT11 (Fig. 1e), a region of 1.2 Mb contain-
ing seven genes (SLC13A3, TP53RK, SLC2A10, EYA2, PRKCBP1,
NCOA3, SULF2) and one pseudogene (RPL35AP). We sequenced
these genes directly and identified homozygous mutations (deletion,
nonsense, missense) in the SLC2A10 gene in all six families (Fig. 2a,b).
In families 1 and 2, we found a homozygous nonsense mutation
510G-A (W170X) in all clinically affected individuals. All affected
individuals in families 3 and 4 were homozygous for frameshift
mutations 961delG (V321fsX391) and 1334delG (G445fsX484),
respectively. Both mutations result in a premature stop codon. The
affected individuals from families 5 and 6 shared the same homo-
zygous missense mutation, 243C-G (S81R). Both families had a
common haplotype between markers mSAT1 and mSAT7, indicating a
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founder mutation in these families (data not shown). We assume that
the latter mutation causes disease on the basis of the following
arguments: (i) Ser81 is evolutionarily strictly conserved in GLUT10
(Fig. 2b); (ii) an uncharged amino acid is changed to a positively
charged amino acid in the third transmembrane domain and (iii) the
mutation was absent in 200 control chromosomes. All parents of
affected individuals (in families 1–6) were heterozygous for the
respective mutations.
The presence of homozygous loss-of-function mutations in at least
four ATS families identifies SLC2A10 as the gene responsible for ATS.
The gene contains five exons and encodes GLUT10, a 541-residue
glucose transporter14–16. Human GLUT10 has been shown to facilitate
D-glucose, D-galactose and 2-deoxy-D-glucose transport when
expressed in Xenopus laevis oocytes4. GLUT10 is an outlier within
the GLUT family because of its longer exofacial loop and differences
in motif characteristics for glucose transporters, suggesting that
GLUT10 may have additional functions, different from other GLUT
family members4,5.
Tissue expression analysis has uncovered a widespread distribution
of SLC2A10 mRNA, mainly in liver, pancreas and adipose tissue4,5,17.
We studied mRNA and protein expression of GLUT10 in cultured
skin fibroblasts and vascular smooth muscle cells (VSMCs) from
individuals affected with ATS and from controls. Quantitative PCR
(Q-PCR) of samples derived from individuals with ATS homozygous
for premature stop codon mutations demonstrated a near-absence of
SLC2A10 mRNA in VSMCs as well as in fibroblasts (Fig. 2c), as
expected by virtue of clearance of mutant transcripts by the nonsense-
mediated mRNA decay (NMD) pathway. We observed normal
SLC2A10 mRNA expression in samples derived from an individual
with ATS homozygous for the 243C-G missense mutation. We
observed (peri)nuclear localization of GLUT10 in normal individuals,
but there was no detectable GLUT10 signal in individuals with ATS,
as shown by immunofluorescence analysis of cultured skin fibro-
blasts and VSMCs (Fig. 2d). An additional argument to suggest
a nuclear localization of GLUT10 is the low dissociation constant
(Km ¼ 0.3 mM), which is compatible with the glucose concentration
in the cytoplasm4.
The SLC2A10 gene has previously been considered as a candidate
gene for diabetes because of its function in glucose transport and its
map position, which coincides with a type 2 diabetes locus4,5.
However, a causal role for SLC2A10 in diabetes has not been demon-
strated18,19. Theoretically, homozygous mutations in SLC2A10 could
lead to ATS, whereas heterozygous mutations could lead to diabetes,
analogous to the situation where homozygous mutations in SLC2A2
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Figure 1 Clinical anomalies in ATS and pedigrees. (a) MR angiography showing typical arterial tortuosity of the cerebral arteries in an individual with
ATS (IV:4 in family 1) in comparison with a healthy aged-matched control. (b) Typical facial phenotype with micrognathia, elongated face, down-slanting
palpebral fissures, blepharophimosis and a beaked nose (individual IV:4 in family 1). (c) Organization of elastic fibers in a control and in an individual with
ATS, as shown by orcein staining. Aorta elastic laminae in the media of an individual with ATS are coarser, less abundant and more disorganized than in
control aorta. Magnification: 400. (d) Pedigree structure of the six ATS families. Symbols: circle, female; square, male; open symbol, unaffected; filled
symbol, affected; slash line, deceased; double relationship line, consanguinity. Asterisks indicate that DNA, fibroblasts or both are available. (e) Ideogram
of chromosome 20 showing the initial linkage interval, the final candidate region and haplotypes for chromosome 20q13.1 markers in the candidate region
in families 1–3.
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lead to Fanconi-Bickel syndrome7 and heterozygous mutations to
diabetes8. However, this hypothesis is unlikely, given that we did not
observe an increased frequency of diabetes in the heterozygotes from
the ATS families.
There is substantial phenotypic overlap between ATS and a newly
identified genetic condition called Loeys-Dietz syndrome (LDS;
OMIM 609192) that associates arterial tortuosity with aneurysm
formation3. Other findings in common between the two conditions
include arachnodactyly, joint laxity or contractions, microretro-
gnathia, hypertelorism, cleft palate and/or bifid uvula (Table 1).
LDS is caused by heterozygous loss-of-function mutations in the
genes encoding the type 1 or type 2 TGFb receptors (TGFBR1 or
TGFBR2). This leads to a paradoxical increase in TGFb signaling
in the arterial wall, as evidenced by increased phosphorylation
and nuclear translocation of Smad2 (pSmad2), a downstream effector
of the TGFb signaling pathway, and increased expression of down-
stream targets of TGFb such as connective tissue growth factor
(CTGF) and collagens3. Because of the clinical overlap with LDS,
we investigated whether the TGFb pathway is involved in the
pathogenesis of ATS.
Immunostaining for pSmad2 and CTGF (Fig. 3a) in the arterial
wall of an individual with ATS demonstrated increased signal intensity
compared with control specimens, similar to the increase observed in
individuals with LDS3. In agreement with the in vivo observations, Q-
PCR measurements showed a significantly higher steady-state mRNA
expression level for CTGF (Fig. 3b) in cultured VSMCs of the
individual with ATS compared with controls (P o 0.05), indicative
of upregulation of TGFb signaling.
The mechanisms by which mutations in SLC2A10 lead to TGFb
activation are unclear. Notably, the expression of decorin, a proteogly-
can inhibitor of TGFb signaling20, is regulated by a defined glucose
response element in its gene promoter21. Therefore, we studied the
expression of decorin in cultured VSMCs of individuals with LDS,
individuals with ATS and controls (Fig. 4). Decorin expression was
severely reduced in cultured VSMCs of individuals with ATS as com-
pared with controls, as shown by immunofluorescence staining
(Fig. 4a). Q-PCR experiments using VSMCs confirmed the reduced
expression of decorin mRNA in individuals with ATS (Fig. 4b). The
specific decrease of decorin expression in individuals with ATS, in
contrast to individuals with LDS, might indicate divergent mechanisms
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Figure 2 SLC2A10 (GLUT10) mutation and expression data. (a) SLC2A10 mutations identified in families 1–6. (b) Location of GLUT10 mutations at a
schematic representation of the GLUT10 protein. GLUT10 contains 12 hydrophobic transmembrane domains (ovals) with a hydrophilic endofacial loop
between transmembrane domains 6 and 7 and a large exofacial loop containing a potential N-linked glycosylation site between transmembrane domains
9 and 10. Evolutionary conservation of the substituted amino acid observed in families 5 and 6 in GLUT10 is shown. (c,d) SLC2A10 (GLUT10) expression
in the control and in individuals with ATS. (c) mRNA expression of SLC2A10 as determined by Q-PCR in VSMCs and skin fibroblasts. In VSMCs in
individuals with ATS, the level of mRNA was severely reduced. In skin fibroblasts, the individual carrying a homozygous nonsense mutation also showed
a significant reduction (P o 0.05) compared with the control, but the individual homozygous for a missense mutation did not show any reduction. Bars
indicate the 95% confidence interval of the mean expression level. (d) Immunofluorescence analysis of GLUT10 in VSMCs and skin fibroblasts. Expression
of GLUT10 was nearly absent in VSMCs and fibroblasts from individuals with ATS, as compared with the control. The fluorescence signal in heterozygous
individuals was approximately half that of the controls. Magnification: 1,000.
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for upregulation of TGFb signaling in these two conditions. Notably,
we did not observe any differences in expression between fibroblasts of
individuals with ATS and those of healthy controls (data not shown).
Given the (peri)nuclear localization of GLUT10, a decrease in intra-
cellular glucose and failure of glucose-mediated transcriptional upre-
gulation of the decorin promoter seems to be unique to ATS. In
contrast, primary alterations in the TGFb receptors lead to increased
TGFb signaling in LDS. In order to determine the specificity of
the decorin response, we monitored the expression of versican, a
proteoglycan that is known not to be strongly regulated by glucose but
whose expression is driven by TGFb22. As predicted from our
pathogenetic model, samples from patients with either ATS or LDS
showed increased expression of versican (Fig. 4c). An inhibitory role
of versican on elastic fiber assembly has been proposed23, perhaps
providing a mechanism for failed elastogenesis in both ATS and LDS.
Although TGFb signaling is disturbed in cells and connective tissue
derived from individuals with ATS, other mechanisms leading to
abnormal matrix deposition cannot be excluded. Impaired uptake or
transport of other monosaccharides could hinder glycosylation events
important for the production of mature glycoproteins and proteogly-
cans, essential structural components of the arterial wall and con-
nective tissue in general.
We were surprised to identify a glucose transporter gene responsible
for a connective tissue disorder. No other connective tissue disorder,
with the exception of pseudoxanthoma elasticum (caused by a muta-
tion in ABCC6), is known to be caused by a transporter protein
defect24. No clear function of the ABCC6 transporter has been identi-
fied, and the underlying pathogenic mechanism leading to disturbed
elastin homeostasis in PXE is unknown. Insights derived from the study
of ATS may prove relevant to other disorders related to failed intra-
cellular transport of glucose. Indeed, the microangiopathic changes and
fibrosis seen in diabetic retinopathy, nephropathy and peripheral
vascular disease correlate with increased TGFb signaling25. Diabetes-
associated arteriolar tortuosity is seen in tissues undergoing postnatal
angiogenesis, including the retinal and coronary microcirculations,
perhaps recapitulating events occurring on a broader scale during
embryogenesis in ATS. These data suggest that antagonism of TGFb
signaling may contribute to therapeutic advances in a wide variety of
genetically determined and acquired disorders, including ATS.
METHODS
Patients. Appropriate informed consent, including specific consent to publish
the photos in Figure 1b, was obtained from all patients involved in the study.
Detailed clinical descriptions of five ATS families, except for family 6, have been
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Figure 3 Immunostaining and Q-PCR analysis for phosphorylated Smad2
and CTGF in arterial tissue. (a) Three controls and individual 5.IV:5 with
ATS were examined. Note the increased intensity of nuclear phosphorylated
Smad2 and extracellular CTGF. Scale bars, 10 mm. (b) Expression levels of
CTGF in VSMCs of affected individual IV:1 of family 4 and two controls in
steady-state conditions, as measured by Q-PCR. CTGF shows fourfold higher
expression in the individual with ATS. Bars indicate the 95% confidence
interval of the mean expression level.
Table 1 Clinical comparison of individuals with ATS and individuals
with LDS
Symptoms ATS LDS
Arterial anomalies
Tortuosity +++ +++
Aneurysms + +++
Stenosis a. pulmonalis ++ 0
Aneurysm a. pulmonalis + ++
Skin laxity +++ +
Skeletal anomalies
Contractures ++ ++
Pectus deformity + ++
Joint laxity +++ +++
Arachnodactyly + ++
Facial anomalies
Hypertelorism + +++
Cleft palate, bifid uvula ++ +++
Microretrognathia +++ ++
0, not described; +, present; ++, common; +++, typical
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Figure 4 Immunofluorescence and Q-PCR analysis of decorin and versican
in VSMC. (a) In individual 4.IV:1 with ATS, expression of decorin is nearly
absent, as compared with control VSMCs. Magnification: 1,000.
(b,c) Q-PCR analysis for (b) decorin and (c) versican in VSMCs of an
individual with ATS compared with an individual with LDS and two controls.
The expression of decorin mRNA in the individual with ATS is significantly
lower (P o 0.05) than in the LDS patient and the controls, whereas
the expression of versican is significantly higher (P o 0.05) in the
individual with ATS and the individual with LDS compared with controls.
Bars indicate the 95% confidence interval of the mean expression level.
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published previously1,12,26. DNA was extracted from peripheral blood and/or
cultured skin fibroblasts. Skin fibroblasts were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 15% fetal bovine serum (FBS) in
the presence of antibiotics. Vascular smooth muscle cells (VSMCs) were
obtained from the aortic media from individual IV:1 with ATS in family 4
and from an individual with LDS (TGFBR1 mutation, R487P)3 and were
cultured in smooth muscle basal medium supplemented 5% FBS, 0.2%
fibroblast growth factor (FGF), 0.1% insulin, 0.1% epidermal growth factor
(EGF), and 0.1% gentamicin sulfate/amphotericin. Paraffin-embedded aortic
tissue was available only from individual IV:5 in family 5.
Microsatellite and sequence analysis. Microsatellite markers in the ATS
linkage region on chromosome 20q13.1 (ref. 2) were taken from the Marshfield
map or designed based on the simple tandem repeat finder in the University of
California Santa Cruz genome browser (mSAT1-11). We carried out genotyping
on an Applied Biosystems Prism 3100 Genetic Analyzer (Applied Biosystems).
The data were processed using Genescan software (Applied Biosystems).
We amplified all coding exons from all seven genes in the ATS linkage
region (SLC13A3, TP53RK, SLC2A10, EYA2, PRKCBP1, NCOA3, SULF2) by
PCR using intronic primers and additional exonic primers for larger
exons (Supplementary Table 1 online). Sequencing was performed using the
BigDye v3.1 ET terminator cycle sequencing kit (Applied Biosystems).
Sequencing reactions were loaded onto an Applied Biosystems Prism 3100
Genetic Analyzer.
Immunostaining. For GLUT10 and decorin analysis in VSMCs and skin
fibroblasts by immunofluorescence microscopy, we grew 1  105 VSMCs or
skin fibroblasts from controls and from individuals with ATS for 72 h in
complete medium. To analyze GLUT10, the cells were washed in PBS,
permeabilized in 0.5% Triton X-100 and 3% paraformaldehyde for 2 min,
fixed for 20 min in 3% paraformaldehyde, incubated for 30 min at room
temperature (21 1C) with 5% BSA/PBS and incubated overnight at 4 1C with
20 mg ml–1 polyclonal antibody to GLUT10 (Alpha Diagnostic). To analyze
decorin levels, the cells were fixed in 3% paraformaldehyde for 10 min, washed
twice for 5 min in PBS and incubated for 40 min at room temperature (21 1C)
with 20 mg ml1 monoclonal antibody to decorin (clone 115402, R&D
Systems). Next, the VSMCs and fibroblasts were incubated for 1 h at room
temperature (21 1C) with rhodamine-conjugated anti-rabbit IgG (1:50 in 1%
BSA/PBS) and anti-mouse IgG (1:100 in 1% BSA/PBS), respectively;
washed in PBS; mounted in 1:1 PBS-glycerol solution on glass slides and
photographed with a Zeiss Axiovert 10S/H fluorescence microscope. Quanti-
tative evaluation of the fluorescence was performed as previously reported27.
For GLUT10, quantitative evaluation was repeated on 20 randomly selected
cells for each cell strain. Images were digitized to measure the cell and the
nuclear areas and the integrated optical density (IOD) corresponding to the
fluorescence signals.
For immunohistochemical staining for CTGF and pSmad2 in arterial tissue,
we selected representative specimens of formalin-fixed, paraffin-embedded
arterial media of three healthy control individuals and one individual with
ATS. From these specimens, 5-mm thick paraffin sections were cut, deparaffi-
nized and rehydrated. These tissues were pretreated with a protease-1 enzy-
matic solution (Ventana). For immunohistochemical analysis, we used
antibodies directed against pSmad2 and CTGF (Alpha Diagnostic, Cell Signal-
ing Technology and Abcam, respectively) and previously described methods3.
Light microscopy was performed on an Olympus BX45 microscope.
Q-PCR. RNA was isolated using the RNeasy Mini Kit (Qiagen), and cDNA was
synthesized using SuperScript II Reverse Transcriptase Kit with random
hexamer primers (Invitrogen) in a total volume of 20 ml. Two microliters of
cDNA (1:10 dilution) and 250 nM gene-specific primers were used with the
Q-PCR Core Kit for SYBR Green I (Eurogentec) for Q-PCR on a GeneAmp
5700 Sequence Detector (Applied Biosystems). The Q-PCR program consisted
of 40 cycles with 15 s at 95 1C and 1 min at 60 1C, followed by a dissociation
run to determine melting curves. We carried out all reactions in duplicate and
normalized them to the geometric mean of three reference genes (GAPDH,
HPRT1 and YWHAZ). We used fibroblasts from controls and individuals with
ATS and VSMCs, obtained from aortic media from two controls, from
individual IV:1 with ATS (from family 4) and from an individual with LDS3.
We grew cells in 6-cm dishes to 80% confluence. Expression levels were
determined in three independent experiments for each cell line. Differential
gene expression was considered significant when the difference was at least 50%
and the 95% confidence interval of the mean expression levels did not overlap
(equivalent to P o 0.05).
Accession codes. GenBank: SLC2A10 cDNA, NM_030777; SLC2A10 coding
region, NT_011362.
Note: Supplementary information is available on the Nature Genetics website.
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